Literature DB >> 21910975

Npc1 deficiency in the C57BL/6J genetic background enhances Niemann-Pick disease type C spleen pathology.

Julio Parra1, Andrés D Klein, Juan Castro, María Gabriela Morales, Matías Mosqueira, Ilse Valencia, Victor Cortés, Attilio Rigotti, Silvana Zanlungo.   

Abstract

Niemann-Pick type C (NPC) disease is an autosomal recessive neurovisceral lipid storage disorder. The affected genes are NPC1 and NPC2. Mutations in either gene lead to intracellular cholesterol accumulation. There are three forms of the disease, which are categorized based on the onset and severity of the disease: the infantile form, in which the liver and spleen are severely affected, the juvenile form, in which the liver and brain are affected, and the adult form, which affects the brain. In mice, a spontaneous mutation in the Npc1 gene originated in the BALB/c inbred strain mimics the juvenile form of the disease. To study the influence of genetic background on the expression of NPC disease in mice, we transferred the Npc1 mutation from the BALB/c to C57BL/6J inbred background. We found that C57BL/6J-Npc1(-/-) mice present with a much more aggressive form of the disease, including a shorter lifespan than BALB/c-Npc1(-/-) mice. Surprisingly, there was no difference in the amount of cholesterol in the brains of Npc1(-/-) mice of either mouse strain. However, Npc1(-/-) mice with the C57BL/6J genetic background showed striking spleen damage with a marked buildup of cholesterol and phospholipids at an early age, which correlated with large foamy cell clusters. In addition, C57BL/6J Npc1(-/-) mice presented red cell abnormalities and abundant ghost erythrocytes that correlated with a lower hemoglobin concentration. We also found abnormalities in white cells, such as cytoplasmic granulation and neutrophil hypersegmentation that included lymphopenia and atypias. In conclusion, Npc1 deficiency in the C57BL6/J background is associated with spleen, erythrocyte, and immune system abnormalities that lead to a reduced lifespan.
Copyright © 2011 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21910975     DOI: 10.1016/j.bbrc.2011.08.096

Source DB:  PubMed          Journal:  Biochem Biophys Res Commun        ISSN: 0006-291X            Impact factor:   3.575


  27 in total

1.  Necroptosis inhibition as a therapy for Niemann-Pick disease, type C1: Inhibition of RIP kinases and combination therapy with 2-hydroxypropyl-β-cyclodextrin.

Authors:  A Cougnoux; S Clifford; A Salman; S-L Ng; J Bertin; F D Porter
Journal:  Mol Genet Metab       Date:  2018-10-30       Impact factor: 4.797

2.  Human and mouse neuroinflammation markers in Niemann-Pick disease, type C1.

Authors:  Stephanie M Cologna; Celine V M Cluzeau; Nicole M Yanjanin; Paul S Blank; Michelle K Dail; Stephan Siebel; Cynthia L Toth; Christopher A Wassif; Andrew P Lieberman; Forbes D Porter
Journal:  J Inherit Metab Dis       Date:  2013-05-08       Impact factor: 4.982

3.  Hepatic entrapment of esterified cholesterol drives continual expansion of whole body sterol pool in lysosomal acid lipase-deficient mice.

Authors:  Amal Aqul; Adam M Lopez; Kenneth S Posey; Anna M Taylor; Joyce J Repa; Dennis K Burns; Stephen D Turley
Journal:  Am J Physiol Gastrointest Liver Physiol       Date:  2014-08-21       Impact factor: 4.052

4.  Ontogenic changes in lung cholesterol metabolism, lipid content, and histology in mice with Niemann-Pick type C disease.

Authors:  Charina M Ramirez; Adam M Lopez; Lam Q Le; Kenneth S Posey; Arthur G Weinberg; Stephen D Turley
Journal:  Biochim Biophys Acta       Date:  2013-09-26

5.  Gastrointestinal Tract Pathology in a BALB/c Niemann-Pick Disease Type C1 Null Mouse Model.

Authors:  Antony Cougnoux; Miyad Movassaghi; Jaqueline A Picache; James R Iben; Fatemeh Navid; Alexander Salman; Kyle Martin; Nicole Y Farhat; Celine Cluzeau; Wei-Chia Tseng; Kathryn Burkert; Caitlin Sojka; Christopher A Wassif; Niamh X Cawley; Richard Bonnet; Forbes D Porter
Journal:  Dig Dis Sci       Date:  2018-01-22       Impact factor: 3.199

6.  Dietary plant stanol ester supplementation reduces peripheral symptoms in a mouse model of Niemann-Pick type C1 disease.

Authors:  Inês Magro Dos Reis; Tom Houben; Yvonne Oligschläger; Leoni Bücken; Hellen Steinbusch; David Cassiman; Dieter Lütjohann; Marit Westerterp; Jos Prickaerts; Jogchum Plat; Ronit Shiri-Sverdlov
Journal:  J Lipid Res       Date:  2020-04-14       Impact factor: 5.922

7.  Maternal immune activation modifies the course of Niemann-pick disease, type C1 in a gender specific manner.

Authors:  Antony Cougnoux; Mason Fellmeth; Tansy Gu; Cristin D Davidson; Alana L Gibson; William J Pavan; Forbes D Porter
Journal:  Mol Genet Metab       Date:  2019-10-17       Impact factor: 4.797

Review 8.  Genetic dissection of a cell-autonomous neurodegenerative disorder: lessons learned from mouse models of Niemann-Pick disease type C.

Authors:  Manuel E Lopez; Matthew P Scott
Journal:  Dis Model Mech       Date:  2013-08-01       Impact factor: 5.758

9.  Tonic prime-boost of STING signalling mediates Niemann-Pick disease type C.

Authors:  Ting-Ting Chu; Xintao Tu; Kun Yang; Jianjun Wu; Joyce J Repa; Nan Yan
Journal:  Nature       Date:  2021-07-21       Impact factor: 49.962

10.  Genomic expression analyses reveal lysosomal, innate immunity proteins, as disease correlates in murine models of a lysosomal storage disorder.

Authors:  Md Suhail Alam; Michelle Getz; Innocent Safeukui; Sue Yi; Pamela Tamez; Jenny Shin; Peter Velázquez; Kasturi Haldar
Journal:  PLoS One       Date:  2012-10-19       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.